<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ipsen Sa — News on 6ix</title>
    <link>https://6ix.com/company/ipsen-sa-1</link>
    <description>Latest news and press releases for Ipsen Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 16:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ipsen-sa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d532debeedb30cb6f6ddbd.webp</url>
      <title>Ipsen Sa</title>
      <link>https://6ix.com/company/ipsen-sa-1</link>
    </image>
    <item>
      <title>Ipsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-sa-information-relating-to-the-holding-of-the-combined-shareholders-meeting-of-13-may-2026-2</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-sa-information-relating-to-the-holding-of-the-combined-shareholders-meeting-of-13-may-2026-2</guid>
      <pubDate>Wed, 22 Apr 2026 16:00:00 GMT</pubDate>
      <description>Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANCE, 22 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 13 May 2026 at 3:00 p.m. (Paris time) at the Salons de l&apos;Hôtel des A</description>
    </item>
    <item>
      <title>Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ojemdar-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ojemdar-approved-in-the-european-union-as-the-first-targeted-therapy-in-relapsed-or-refractory-pediatric-low-grade-glioma-regardless-of-braf-alteration-1</guid>
      <pubDate>Wed, 22 Apr 2026 05:00:00 GMT</pubDate>
      <description>New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda® (tovorafenib) represents a rare achievement that reinforces the urgent need to close the innovation and investment gaps in pediatric therapeuticsApproval is based on pivotal Phase II FIREFLY-1 datai demonstrating meaningful and durable tumor responses PARIS, FRANCE, 22 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) today</description>
    </item>
    <item>
      <title>Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-that-beech-tree-has-obtained-an-exemption-from-the-obligation-to-submit-a-public-tender-offer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-that-beech-tree-has-obtained-an-exemption-from-the-obligation-to-submit-a-public-tender-offer-1</guid>
      <pubDate>Fri, 03 Apr 2026 05:00:00 GMT</pubDate>
      <description>PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.’s share capital and 33.05% of its voting rights — has obtained from the French Financial Markets Authority (Autorité des marchés financiers) an exemption from the obligation to file a public tender offer for all Ipsen S.A. shares.1 This decision is part of the transfer of Mr. Henri Beaufour’s stake in Beech Tree to the Alasol Foundation. This transf</description>
    </item>
    <item>
      <title>Ipsen announces the availability of its 2025 Universal Registration Document</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-the-availability-of-its-2025-universal-registration-document-4</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-announces-the-availability-of-its-2025-universal-registration-document-4</guid>
      <pubDate>Wed, 01 Apr 2026 16:00:00 GMT</pubDate>
      <description>Ipsen announces the availability of its 2025 Universal Registration Document PARIS, FRANCE, 1 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced that its 2025 Universal Registration Document has been filed today with the French Autorité des Marchés Financiers (AMF) and registered under the number D.26-0202. The document is available on www.ipsen.com and www.amf-france.org. Copies will also be available at Ipsen’s headquarters – 70 rue Balard, 75015 Paris, France. The Universal Registration</description>
    </item>
    <item>
      <title>Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-february-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-492</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-february-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-492</guid>
      <pubDate>Fri, 13 Mar 2026 17:00:00 GMT</pubDate>
      <description>Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)28 February 2026 83,814,526 Gross total* of voting rights: 131,963,662Net total**</description>
    </item>
    <item>
      <title>Ipsen appoints Michelle C. Werner as EVP, President of North America</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-appoints-michelle-c-werner-as-evp-president-of-north-america-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-appoints-michelle-c-werner-as-evp-president-of-north-america-1</guid>
      <pubDate>Thu, 12 Mar 2026 06:30:00 GMT</pubDate>
      <description>Michelle C. Werner Photo of Michelle C. Werner, EVP, President of North America PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “I am very pleased to welcome Michelle to Ipsen and to the Executive Leader</description>
    </item>
    <item>
      <title>Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/update-ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/update-ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</guid>
      <pubDate>Mon, 09 Mar 2026 17:37:00 GMT</pubDate>
      <description>PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hemat</description>
    </item>
    <item>
      <title>Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-voluntarily-withdraws-tazverikr-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma-1</guid>
      <pubDate>Mon, 09 Mar 2026 06:00:00 GMT</pubDate>
      <description>PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hemat</description>
    </item>
    <item>
      <title>Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-receives-positive-chmp-opinion-for-ojemdar-for-the-treatment-as-monotherapy-of-children-with-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-receives-positive-chmp-opinion-for-ojemdar-for-the-treatment-as-monotherapy-of-children-with-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma-1</guid>
      <pubDate>Fri, 27 Feb 2026 11:20:00 GMT</pubDate>
      <description>If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE, 27 FEBRUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced to</description>
    </item>
    <item>
      <title>GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/genfit-to-receive-usdollar20m-milestone-after-ipsens-iqirvor-exceeds-the-usdollar200m-threshold-in-its-first-full-year-of-net-sales-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/genfit-to-receive-usdollar20m-milestone-after-ipsens-iqirvor-exceeds-the-usdollar200m-threshold-in-its-first-full-year-of-net-sales-1</guid>
      <pubDate>Thu, 12 Feb 2026 17:35:00 GMT</pubDate>
      <description>Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout and recommended Phase 2 doses</description>
    </item>
    <item>
      <title>Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-delivers-strong-results-in-2025-driven-by-solid-execution-across-all-therapeutic-areas-and-provides-2026-guidance-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-delivers-strong-results-in-2025-driven-by-solid-execution-across-all-therapeutic-areas-and-provides-2026-guidance-1</guid>
      <pubDate>Thu, 12 Feb 2026 06:00:00 GMT</pubDate>
      <description>FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points2025 continued pipeline expansion, driven by</description>
    </item>
    <item>
      <title>Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-january-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-january-2026-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-1</guid>
      <pubDate>Mon, 09 Feb 2026 17:30:00 GMT</pubDate>
      <description>Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)31 January 202683,814,526Gross total* of voting rights: 131,997,884Net total** of</description>
    </item>
    <item>
      <title>Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/origami-therapeutics-announces-global-collaboration-with-ipsen-to-advance-protein-degrader-program-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/origami-therapeutics-announces-global-collaboration-with-ipsen-to-advance-protein-degrader-program-1</guid>
      <pubDate>Fri, 30 Jan 2026 17:00:00 GMT</pubDate>
      <description>SAN DIEGO, January 30, 2026--Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program</description>
    </item>
    <item>
      <title>Ipsen nominates Peter Guenter to its Board of Directors</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-nominates-peter-guenter-to-its-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-nominates-peter-guenter-to-its-board-of-directors-1</guid>
      <pubDate>Thu, 29 Jan 2026 06:00:00 GMT</pubDate>
      <description>Ipsen Board of Directors Peter Guenter Ipsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026. PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position. Peter Guenter holds nearly 40 years of experience as an executive leader in the global pharmaceutical industry. Most recently,</description>
    </item>
    <item>
      <title>Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/pierrick-lefranc-appointed-as-executive-vice-president-technical-operations-member-of-executive-leadership-team-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/pierrick-lefranc-appointed-as-executive-vice-president-technical-operations-member-of-executive-leadership-team-1</guid>
      <pubDate>Tue, 27 Jan 2026 06:00:00 GMT</pubDate>
      <description>Pierrick Lefranc EVP Technical Operations Pierrick Lefranc appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026 PARIS, FRANCE, 27 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026. Pierrick will succeed Aidan Murphy, EVP Technical Operations and Member of the ELT, who after 30 ye</description>
    </item>
    <item>
      <title>Arbitration tribunal upholds Ipsen’s termination of R&amp;D agreement with Galderma</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/arbitration-tribunal-upholds-ipsens-termination-of-randd-agreement-with-galderma-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/arbitration-tribunal-upholds-ipsens-termination-of-randd-agreement-with-galderma-1</guid>
      <pubDate>Wed, 21 Jan 2026 16:45:00 GMT</pubDate>
      <description>PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&amp;D agreement. The ICC Tribunal’s decision confirms Ipsen’s full rights to its clinical stage toxin programs in the aesthetic field. “This decisive ICC ruling supports Ipsen’s leadership pos</description>
    </item>
    <item>
      <title>New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/new-data-reinforces-ipsens-commitment-to-bringing-solutions-and-addressing-care-gaps-in-neurological-diseases-at-toxins-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/new-data-reinforces-ipsens-commitment-to-bringing-solutions-and-addressing-care-gaps-in-neurological-diseases-at-toxins-1</guid>
      <pubDate>Wed, 14 Jan 2026 06:00:00 GMT</pubDate>
      <description>14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement disordersInterim data from the ongoing EPITOME trial1 showed that 45.7% of stroke survivors with paresis developed post-stroke spasticity within 1 year&lt;1% of stroke survivors receive BoNT-A treatment for spasticity in routine practice2 PARIS, FRANCE, 14 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of 14</description>
    </item>
    <item>
      <title>U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/us-fda-grants-ipsens-ipn60340-ict01-breakthrough-therapy-designation-in-first-line-unfit-acute-myeloid-leukemia-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/us-fda-grants-ipsens-ipn60340-ict01-breakthrough-therapy-designation-in-first-line-unfit-acute-myeloid-leukemia-1</guid>
      <pubDate>Tue, 13 Jan 2026 17:19:00 GMT</pubDate>
      <description>Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia PARIS, FRANCE, 13 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza) in first line unfit acute myeloid leukemia, an aggressive blood cancer affectin</description>
    </item>
    <item>
      <title>Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-december-2025-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-december-2025-monthly-information-relative-to-the-total-number-of-voting-rights-and-shares-composing-the-share-capital-1</guid>
      <pubDate>Wed, 07 Jan 2026 17:30:00 GMT</pubDate>
      <description>Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)31 December 202583,814,526Gross total* of voting rights: 132,013,627Net total** o</description>
    </item>
    <item>
      <title>Ipsen – Half year statement – 2025 12 31</title>
      <link>https://6ix.com/company/ipsen-sa-1/news/ipsen-half-year-statement-2025-12-31-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ipsen-sa-1/news/ipsen-half-year-statement-2025-12-31-1</guid>
      <pubDate>Tue, 06 Jan 2026 17:00:00 GMT</pubDate>
      <description>Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, 06 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that under the liquidity agreement entrusted by IPSEN S.A. to NATIXIS ODDO BHF, as of December 31, 2025, the following resources were included to the dedicated liquidity account: 30,064 shares €2,126,437.66 It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account: 12,751 shares€3</description>
    </item>
  </channel>
</rss>